Zhang Chunlei, Wang Yong, Cheng Lei, Cao Xiansheng, Liu Chunyuan
Department of Colorectal and Anus Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Department of Hepatobiliary Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China.
Front Oncol. 2025 Mar 5;15:1557959. doi: 10.3389/fonc.2025.1557959. eCollection 2025.
Colorectal cancer (CRC) poses a significant global health burden, with gut microbiota emerging as a crucial modulator of CRC pathogenesis and therapeutic outcomes. This review synthesizes current evidence on the influence of gut microbiota on tumor immune surveillance and responses to immunotherapies and chemotherapy in CRC. We highlight the role of specific microbial taxa in promoting or inhibiting tumor growth and the potential of microbiota-based biomarkers for predicting treatment efficacy. The review also discusses the implications of microbiota modulation strategies, including diet, probiotics, and fecal microbiota transplantation, for personalized CRC management. By critically evaluating the literature, we aim to provide a comprehensive understanding of the gut microbiota's dual role in CRC and to inform future research directions in this field.
结直肠癌(CRC)给全球健康带来了重大负担,肠道微生物群已成为CRC发病机制和治疗结果的关键调节因子。本综述综合了当前关于肠道微生物群对CRC肿瘤免疫监视以及对免疫疗法和化疗反应影响的证据。我们强调了特定微生物分类群在促进或抑制肿瘤生长中的作用,以及基于微生物群的生物标志物预测治疗效果的潜力。该综述还讨论了微生物群调节策略,包括饮食、益生菌和粪便微生物群移植,对CRC个性化管理的意义。通过严格评估文献,我们旨在全面了解肠道微生物群在CRC中的双重作用,并为该领域未来的研究方向提供参考。